[{"address1": "5 Science Park", "address2": "395 Winchester Avenue", "city": "New Haven", "state": "CT", "zip": "06511", "country": "United States", "phone": "(203) 535-1456", "website": "https://www.arvinas.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.", "fullTimeEmployees": 430, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ian  Taylor Ph.D.", "age": 62, "title": "President of Research & Development and Chairman of Scientific Advisory Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 732256, "exercisedValue": 0, "unexercisedValue": 1344633}, {"maxAge": 1, "name": "Mr. Andrew R. Saik", "age": 55, "title": "CFO & Treasurer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.67, "open": 17.61, "dayLow": 17.19, "dayHigh": 18.32, "regularMarketPreviousClose": 17.67, "regularMarketOpen": 17.61, "regularMarketDayLow": 17.19, "regularMarketDayHigh": 18.32, "beta": 1.884, "forwardPE": -4.345793, "volume": 934540, "regularMarketVolume": 934540, "averageVolume": 920738, "averageVolume10days": 1161230, "averageDailyVolume10Day": 1161230, "bid": 18.22, "ask": 18.39, "bidSize": 300, "askSize": 400, "marketCap": 1259213568, "fiftyTwoWeekLow": 16.61, "fiftyTwoWeekHigh": 51.99, "priceToSalesTrailing12Months": 4.7806134, "fiftyDayAverage": 19.3734, "twoHundredDayAverage": 25.1861, "currency": "USD", "enterpriseValue": 229512880, "profitMargins": -0.75513, "floatShares": 53835305, "sharesOutstanding": 68771904, "sharesShort": 10436151, "sharesShortPriorMonth": 9479102, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1517, "heldPercentInsiders": 0.07209, "heldPercentInstitutions": 1.10584, "shortRatio": 12.89, "shortPercentOfFloat": 0.15439999, "impliedSharesOutstanding": 68771904, "bookValue": 8.164, "priceToBook": 2.2427733, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -198900000, "trailingEps": -2.77, "forwardEps": -4.66, "enterpriseToRevenue": 0.871, "enterpriseToEbitda": -0.934, "52WeekChange": -0.6381423, "SandP52WeekChange": 0.22894537, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ARVN", "underlyingSymbol": "ARVN", "shortName": "Arvinas, Inc.", "longName": "Arvinas, Inc.", "firstTradeDateEpochUtc": 1538055000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "5ab3d208-4f36-3880-916e-a34548e61b36", "messageBoardId": "finmb_243040896", "gmtOffSetMilliseconds": -18000000, "currentPrice": 18.31, "targetHighPrice": 110.0, "targetLowPrice": 28.0, "targetMeanPrice": 60.7, "targetMedianPrice": 58.5, "recommendationMean": 1.40909, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 20, "totalCash": 1039400000, "totalCashPerShare": 15.114, "ebitda": -245600000, "totalDebt": 9700000, "quickRatio": 4.583, "currentRatio": 4.644, "totalRevenue": 263400000, "debtToEquity": 1.727, "revenuePerShare": 3.663, "returnOnAssets": -0.13053, "returnOnEquity": -0.32561, "grossProfits": 263400000, "freeCashflow": -99275000, "operatingCashflow": -259300000, "grossMargins": 1.0, "ebitdaMargins": -0.93241996, "operatingMargins": -0.98310995, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]